fbpx
Connect with us

News

Pfizer to acquire ReViral in $525 million deal

Published

on

Biopharmaceutical company ReViral Ltd has entered into a definitive agreement to be acquired by Pfizer for up to US$525 million in total deal value.

Founded in 2011, ReViral discovers, develops and commercialises novel antiviral therapeutics that target respiratory syncytial virus (RSV).

RSV is a respiratory pathogen which can lead to severe and life-threatening lower respiratory tract infections (LRTIs) in high-risk populations.

ReViral’s lead drug sisunatovir has been designed to block the fusion of RSV to the host cell.

The orally administered inhibitor has been granted Fast-Track designation by the US Food and Drug Administration (FDA).

Alex C. Sapir, Chief Executive Officer, ReViral, said:

“This acquisition represents a validation of the deep antiviral experience of the ReViral team and our unwavering commitment to delivering therapies for patients in need.

“Pfizer is an optimal partner given its commitment to RSV through the ongoing RSV vaccine programme coupled with world-class clinical, regulatory, manufacturing, and commercial capabilities.”

Novo Ventures, the venture capital team at Novo Holdings, led Novo Holdings’ first investment in ReViral in July 2018 co-leading a US$55 million Series B financing.

Since January 2020, Novo Ventures has helped deploy over US$1.1 billion in life science investments, including in infectious diseases.

Naveed Siddiqi, Board Director of ReViral and Senior Partner, Novo Holdings, said:

“The proposed acquisition of the Company by Pfizer confirms the promise of ReViral’s pipeline of novel RSV therapeutics.

“As a leading transatlantic investor, Novo Holdings has a 20-year record of backing and supporting experienced management teams in developing transformative therapies for the benefit of patients.

“Pfizer is an ideal partner to take ReViral’s important mission forward.”

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending stories